Obalon Therapeutics

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ: OBLN) in connection with the proposed merger of the Company...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.

Addex Therapeutics

Genetic Technologies

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone. Genetic Technologies is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health.

Why Addex, Genetic Technologies And Obalon Are Moving Today

The stock price of Obalon Therapeutics Inc (NASDAQ: OBLN) increased by 414.29%. This is why it happened.

OBLN Stock Price Increased By 414.29% Today: Why It Happened

Shares of medical technology company Obalon Therapeutics exploded 568% to as high as $10.71 on Wednesday following a merger announcement with weight-loss company ReShape Lifesciences. Obalon's stock reached an intraday high of $10.77 around 2:00 pm ET Wednesday, a 568% upside from Tuesday's closing price of $1.61. Trading volume of the stock soared to 370 million shares, compared to the average volume of 4.2 million shares traded per day. Meanwhile, ReShape Lifesciences grew as much as 250% to $14 on Wednesday.

Obalon Therapeutics skyrockets 568% after announcing merger with weight-loss company ReShape Lifesciences (OBLN)

Obalon Therapeutics Inc (NASDAQ: OBLN) shares are trading higher Wednesday after the company announced a merger agreement with ReShape Lifesciences. Obalon Therapeutics is a medical device company that focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss.

Obalon Surges 470% On ReShape Lifesciences Merger Agreement

Shares of Obalon Therapeutics Inc. blasted five-fold higher on massive volume in midday trading Wednesday, after the weight loss technologies company announced an agreement to merge with weight loss solutions company ReShape Lifesciences Inc. . Obalon's stock rose 401.6% toward the highest close since July 2019, while trading volume soared to 250.3 million shares, compared with the full-day average of about 626,000 shares.

Obalon Therapeutics stock soars to lead all gainers on massive volume after merger with ReShape

Obalon Therapeutics (OBLN) stock is skyrocketing on Wednesday after announcing merger plans with ReShape Lifesciences (RSLS). The post OBLN Stock: 12 Things to Know About the ReShape-Obalon Merger as Shares Balloon Higher appeared first on InvestorPlace.

OBLN Stock: 12 Things to Know About the ReShape-Obalon Merger as Shares Balloon Higher

Obalon Therapeutics (OBLN) stock is skyrocketing higher Monday on heavy trading despite a lack of news from the medical device company. The post OBLN Stock: 11 Things to Know About Weight Loss Balloon Play Obalon Therapeutics appeared first on InvestorPlace.

OBLN Stock: 11 Things to Know About Weight Loss Balloon Play Obalon Therapeutics

Obalon Therapeutics's (NASDAQ: OBLN) stock has been rising Monday, up 121.49% to a price of $1.9. The stock's volume is currently 17.38 million, which is roughly 1879.95% of its recent 30-day volume average of 924.91 thousand.

Why Is It Moving? Analyzing The Upward Movement in Obalon Therapeutics's Stock Today

After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as we share valuable insight into the smart money sentiment towards Obalon Therapeutics, Inc. (NASDAQ:OBLN).

Is Obalon Therapeutics, Inc. (OBLN) A Good Stock To Buy?

SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020.

Obalon Announces Third Quarter 2020 Financial Results

SAN DIEGO, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability.

Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System

SAN DIEGO, July  30, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020.

Obalon Announces Second Quarter 2020 Financial Results

SAN DIEGO, June  19, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

Obalon Announces First Quarter 2020 Financial Results and Business Update

SAN DIEGO, May  11, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options.

Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment

Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position Obalon’s Executive Chairman, Andy Rasdal, will reassume CEO position

William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director

Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA Obalon reported no device-related serious adverse events (0%) for first 141 patients completing therapy in post-approval study to FDA

Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons

SAN DIEGO, March  25, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor.

Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives

No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority No patients or employees have been found to be symptomatic or positive for the virus, yet patient, employee, and public health remain Obalon’s highest priority

Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic

Obalon Therapeutics, Inc. (OBLN) CEO Bill Plovanic on Q4 2019 Results - Earnings Call Transcript

Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™ Company continues to execute on its strategy to develop retail treatment sites focused exclusively on treatment with the Obalon Balloon System™

Obalon Announces Opening of Second Retail Treatment Center in Orange County, CA

SAN DIEGO, Feb.  07, 2020  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a new common stock purchase agreement and registration rights agreement (together, the “Agreements”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $15 million. The new Agreements replace existing agreements between the Company and LPC.

Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capital Fund

Is  (OBLN) Outperforming Other Medical Stocks This Year?

Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?

SAN DIEGO, Dec.  18, 2019  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a one-year agreement with Al Danah Medical Company (“Al Danah”) for distribution of the Obalon Navigation Balloon System in Qatar.  Obalon has terminated its agreement with Bader Sultan and Bros. Company for distribution of its prior-generation balloons, which was set to expire on December 31, 2019. Obalon’s President and CEO, Bill Plovanic commented, “While our primary focus is on the development and operation of Company-owned retail treatment centers in the U.S., we recognize that obesity remains a global epidemic. We believe the agreement with Al Danah makes clinical and economic sense and allows us to take a small step forward internationally, without distracting us from our primary commercial strategy in the United States.”  About Obalon Therapeutics, Inc.   Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit  http://www.obalon.com .

Obalon Enters into a Distribution Agreement for Qatar

Obalon Therapeutics, Inc. (OBLN) Management on Q3 2019 Results - Earnings Call Transcript

News for Obalon Therapeutics Stock (OBLN)